BRAINTEASER Focus Groups: suitable exploitation routes co-design first online workshop

16th February 2022

The first out of four BRAINTEASER Focus Groups dedicated to the project’s results exploitation and sustainability, was held on February 1st 2022.

These exploitation Focus Groups aim to broaden the project’s vision on users and market needs, obtaining additional requirements and at accompanying the BRAINTEASER Consortium towards the most suitable results’ sustainability and commercialisation strategy.

The aim of the first online workshop was to offer an overview of the BRAINTEASER project as a whole, shedding light on the clinical apps and tools under development.

By implementing the principles of participatory design, a group of outstanding experts have been engaged in this first gathering and have animated the plenary discussion with views and suggestions to assess and enhance the BRAINTEASER solutions and its exploitation approach.

The panel of speakers was composed of : Patients Associations (Pedro Carrascal – European Multiple Sclerosis Platform President and Patricia Jarabo Blázquez – Fundación Luzón), Medical and scientific experts (Andrea Caffo – EUPALS), ICT Specialists (Peter Wu – ASUSCloud CEO), Policy Regulators  (Daniele Bollati – IMQ Product reviewer and Lead Auditor), Ethical Experts (Sofia Ortet – Nursing School of Coimbra and Vojin Rakic – University of Belgrade · Center for the Study of Bioethics, European Division of the UNESCO Chair of Bioethics, Institute for Social Sciences, Belgarde) and Standardisation Experts (Catherine Chronaki – HL7 Europe Secretary General).

 Watch the workshop recording here:

YouTube

By loading the video, you agree to YouTube’s privacy policy.
Learn more

Load video

BRAINTEASER is a data science project that seeks to exploit the value of large clinical datasets integrated with personal and environmental data collected through low-cost sensors, to develop AI-based clinical software and mobile apps to support patients with amyotrophic lateral sclerosis and multiple sclerosis and their clinicians.

Recent posts
EnglishFrenchItalianPortugueseSpanish